Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Hospira UK Limited, Horizon, Honey Lane, Hurley, Maidenhead, SL6 6RJ, United Kingdom
Tomudex 2 mg powder for solution for infusion.
| Pharmaceutical Form |
|---|
|
Powder for solution for infusion. White to cream coloured powder. |
One vial contains 2 mg raltitrexed.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Raltitrexed |
Raltitrexed is a folate analogue belonging to the family of anti-metabolites and has potent inhibitory activity against the enzyme thymidylate synthase (TS). Compared to other antimetabolites such as 5-fluorouracil or methotrexate, raltitrexed acts as a direct and specific TS inhibitor. TS is a key enzyme in the de novo synthesis of thymidine triphosphate (TTP), a nucleotide required exclusively for deoxyribonucleic acid (DNA) synthesis. Inhibition of TS leads to DNA fragmentation and cell death. |
| List of Excipients |
|---|
|
Mannitol |
5 ml clear neutral type I glass vials, with a bromobutyl rubber closure and aluminium crimp seal with a plastic flip-off cover.
The vials are packed in individual cartons to protect the product from light.
Hospira UK Limited, Horizon, Honey Lane, Hurley, Maidenhead, SL6 6RJ, United Kingdom
PL 04515/0225
Date of first authorisation: 25 June 2000
| Drug | Countries | |
|---|---|---|
| TOMUDEX | Austria, Australia, Canada, Spain, France, Malta, Turkey, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
